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Abstract 
Epidemiologic studies of hormone therapy (HT) and colorectal cancer incidence consistently 
show an inverse association; however, few studies considered prediagnostic use of HT on 
mortality among colorectal cancer patients.  We evaluated the relationship of HT and survival 
among a population-based cohort of women with large bowel cancer. Cases (n=1297) were 
newly diagnosed with invasive cancer of the colon or rectum, aged 40-74 years at diagnosis, who 
were identified by Wisconsin’s statewide registry (1988-1991; 1997-2001) for two case-control 
studies.   Information on HT use and other colorectal cancer risk factors was collected by 
standardized interview. There were 507 deaths (274 of these attributable to colorectal cancer) 
over 8.4 years of follow-up through December 2005.  Hormone use was not associated with 
colorectal cancer mortality (Adjusted hazard rate ratio=1.09, confidence interval=0.81-1.47).  
Colorectal cancer specific mortality was not associated with HT when considered separately by 
preparation type or combined.  Stage did not modify this relationship.  Long-term HT was 
weakly positively associated with increased mortality after diagnosis of proximal colon, but not 
distal colon cancer.  Because we detected no differences in survival among users of HT 
compared to non-users, the results suggest that HT use may affect the incidence of only some 
colorectal tumors. 
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Introduction 
 
Hormones clearly play a role in large bowel health, both through direct and indirect 
mechanisms[1]. Observational studies and randomized controlled trials of colorectal cancer have 
been remarkably consistent in demonstrating 20-40% reduction in risk in current users of 
hormone therapy (HT) [2-11], including an almost 40% reduction in risk that was reported for 
current HT use in a randomized controlled trial [5, 12].  It is not clear, though, what effects the 
use of prediagnostic hormone therapy may have on subsequent mortality after colorectal cancer 
diagnosis.  Two cohort studies in women with colorectal cancer, who were then followed-up for 
mortality, have observed associations between HT use and reduced risk of death from colorectal 
cancer, although associations within subsite were inconsistent [13, 14].  These studies were 
unable, however, to adjust for several important confounders, including screening [13, 14].  In a 
large cohort of healthy women, HT use was associated with a reduced risk of colorectal cancer 
mortality [15], but this design could not distinguish HT effects on incidence from those of 
survival.  More recently, results from a HT trial indicated no association between conjugated 
equine estrogens and colorectal cancer mortality, though numbers of deceased women were 
small: 20 and 16 women deceased for the intervention and placebo groups, respectively [16].  
Although many women have discontinued use of HT following the publication of the results of 
recent HT trials [7, 17], nearly 50% of women aged 50-65 years have ever used HT, and about 
12% still continue to do so [18].  We had an opportunity to evaluate the relationship between HT 
and mortality in a cohort of colorectal cancer cases based upon our earlier case-control studies of 
colorectal cancer in women [8, 19].  
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Materials and Methods 
This analysis was conducted using pooled data from two case-control studies that used similar 
designs and questionnaires.  Both studies were approved by the Institutional Review Board at the 
University of Wisconsin-Madison in accord with assurances filed with and approved by the U.S. 
Department of Health and Human Services. 
 
Identification of cases 
This study retrospectively followed all cases who were enrolled in our previous case-control 
studies, which included female Wisconsin residents, ages 40-74 years, with an incident diagnosis 
of colorectal cancer during two periods: from 1988-1991 and 1997-2001.  These studies have 
been previously described in detail, including differences in baseline characteristics between the 
two study phases [19, 20]. Briefly, diagnostic reports, including information on cancer site, 
histology, extent of disease, and follow-up physician, were obtained from Wisconsin’s 
mandatory population-based cancer registry.  Eligibility for the case-control study was limited to 
cases with listed telephone numbers and without prior diagnosis of colorectal cancer.  The 
physician of record for each eligible case was contacted by mail to request permission to contact 
the woman.  Of the 2,209 eligible cases, physicians refused contact for 129 (6%), 370 (17%) 
were found to be deceased, 211 (9%) refused to participate, 26 (1%) were unable to be located, 
and 4 (0.2%) interviews were deemed unreliable.  Thus, data for 1,469 women were collected, 
with similar response rates in the two time periods, and for an overall response rate of 67%.  
Cases under the age of 40 years (n=31) or with incomplete information on hormone therapy use 
(n=90) were excluded from the analysis; therefore 1,348 cases were included in this study.  The 
following classifications were used for colon subsite analyses: cancer of the proximal colon 
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included sites from the cecum to the tranverse colon (International Classification of Diseases for 
Oncology (ICD-O) codes C18.0-18.4 [21]), and cancers of the distal colon included sites from 
the splenic flexure to the rectum (ICD-O codes: C18.5-C18.7, C19.9). Multiple and not 
otherwise specified (NOS) sites (ICD-O codes: C18.8-9) were excluded from subsite analyses. 
Extent of disease was reported by the registry as local, regional, distant, or unknown. 
 
Data collection  
All cases completed a standardized 40-minute telephone interview that elicited information on 
use of HT.  Only exposures prior to diagnosis were included by asking women to report 
exposures occurring in the year prior to diagnosis or on average two years prior to interview.  
There were slight variations in the questionnaire format for the two study periods; all versions 
elicited a standard history of HT, including types, duration, age at initial use, and time since last 
use.  HT use was defined as the use of oral, injectable, or transdermal non-contraceptive 
hormones for 3 months or more.  Other risk factors for colorectal cancer were also collected, 
including reproductive and menstrual history, physical activity, current and past height and 
weight, medication use, screening by endoscopy and/or fecal occult blood test, family history of 
colorectal cancer, alcohol consumption, smoking history, medical history, and demographic data.  
Information about the cases’ personal and family history of colorectal cancer was obtained at the 
end of the interview to maintain blinding.  The interviewers were unaware of the disease status 
of the subjects until the end of the interview for 78% of cases. 
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Identification of deaths 
Outcomes that occurred after the completion of a case’s interview and before the end of follow-
up on December 31, 2005 were included.  The vital status of study participants was determined 
using name, date of birth, and social security number (when available) to link with death records.  
First, the death certificate data from the Wisconsin Vital Records Office were searched for 
deaths.  For cases not reported to be deceased in the state vital records, we used automated 
linkages with the National Death Index [22].  For all deaths, we ascertained underlying cause of 
death, assigned according to the International Classification of Diseases Tenth Revision.  The 
primary endpoint was death from colon cancer (ICD-10 codes C18-C20, C26.0), but we also 
examined death from any cause.  When there was a discrepancy between anatomic site between 
death certificate and cancer registry data, we assigned the anatomic site at death to that reported 
by cancer registry, because cause of death may be misclassified on death certificates.   
 
Statistical analyses 
For women who were deceased, survival was calculated as the number of months from date of 
diagnosis to date of death.  For all other women, survival was censored on December 31, 2005.  
Cox proportional hazards models were used to estimate the adjusted hazard rate ratio (HRR) and 
corresponding 95% confidence intervals for colorectal and all-cause mortality according to HT 
use [23].  HT use was characterized as “any use”, exclusive use of estrogen–alone, and exclusive 
use of estrogen-progestin.  We examined use according to any use (”ever”), recency (current or 
former) and total duration of use. “Any” HT use included exclusive estrogen-alone and estrogen- 
progestin users as well as women who used both types of preparations at various times.  A 
woman was defined as a current user of HT if she reported use in the calendar year before the 
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diagnosis.  Women were classified as postmenopausal if they reported having a natural 
menopause or hysterectomy with bilateral oophorectomy by the date of diagnosis.  Women who 
underwent hysterectomy without bilateral oophorectomy were considered postmenopausal if 
they reached the age at which natural menopause occurred in 90% of the cohort (54.4 years for 
smokers, 55 years for non-smokers).  
 
There were differences between the two study phases for some baseline characteristics; oral 
contraceptive use and body mass index were higher for both cases and controls in the second 
phase, and screening was higher in the second phase for cases only [19].  Thus, all regression 
models were stratified on phase of study and exact age at diagnosis.  Confounders, chosen a 
priori, that were adjusted for in multivariable models included body mass index (by quartiles in 
kg/m2), menopausal status, endoscopy screening history (never, ever), smoking status (never, 
ever), and family history of cancer (absent, present), and time from date of diagnosis to 
interview. Additional exploratory analyses were conducted to examine whether age at diagnosis 
(<70 versus ≥70 years), stage of disease (localized versus regional/distant), and endoscopy 
screening history (no versus yes) modified these associations.  All analyses were performed 
using SAS 9.1 software (SAS Institute, Inc., Cary, NC).   
 
Results  
Women using HT were more likely to be younger, have localized disease, were slightly leaner, 
and ever smokers (Table 1) compared to non-users.  Approximately 40% of HT users reported a 
history of regular endoscopy screening, compared with only 32% of non-users.  
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After a mean follow-up of 8.4 years (range 1-18 years), there were 507 deaths, with 274 
attributed to colon or rectal cancer.  Overall there was no association between use of HT and 
colorectal cancer mortality (Table 2).  No associations were observed between recency of use 
and colorectal cancer mortality in either current users (HRR=1.25, 95% CI 0.87-1.81) or former 
users (HRR=0.87, 95% CI, 0.55-1.35).  Increasing time (per year) since last use of HT was 
associated with a modest reduction in risk (HRR=0.95, 95% CI, 0.91-0.99), although no trends 
were observed with increasing duration of use (HRR=1.01 (per year), 95% CI, 0.99-1.04).  
Neither exclusive estrogen–alone, nor estrogen–progestin preparations were associated with 
colorectal cancer mortality.  
  
The results from analyses stratified by site of colorectal cancer were similar to the overall 
colorectal cancer mortality results (Table 2).  However, among proximal colon cancer cases, an 
increased risk of mortality was associated with increasing duration of HT use compared to HT 
non-users (HRR=1.04 per year, 95% CI, 1.00-1.07).  However, when examining time since last 
use of HT, a reduction in risk was observed with a 0.87 reduction in risk for each additional year 
since last use (95% CI, 0.78-0.98). These site-specific risks did not appear to differ by type of 
HT preparation, and no associations were observed among distal colon cases.  Risks also 
appeared to be similar by extent of disease, although small numbers of deaths occurring among 
women with localized disease limited this analysis. 
 
Death from any cause was not related to use of HT, with no differences in risk comparing HT 
users with non-users (HRR=0.87, 95% CI 0.69-1.09).  The associations with HT and all-cause 
mortality, stratified by site of initial cancer, were similar to those overall (Table 3).  Again, 
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among proximal colon cancer cases there was a suggestion of an increased risk of death from all-
causes associated with increasing years of HT use (HRR=1.03, 95% CI, 1.00-1.06, Table 3). 
There was no association between HT among women diagnosed with distal colon cancer, nor 
were there statistically significant associations between type of HT used, and all-cause mortality.    
 
Age at diagnosis, stage of disease, and history of screening did not modify these associations, 
and no associations were statistically significant after stratifying by these variables.  The risk of 
colorectal cancer mortality associated with HT use was 0.63 (95% CI, 0.27-1.44) among women 
who had localized disease (ndeceased=8), and 1.17 (95% CI, 0.84-1.64) among women with 
regional/distant disease (ndeceased=51).  The risk of colorectal cancer mortality associated with HT 
use was 0.92 (95% CI, 0.62-1.36) among women who had not been screened (ndeceased=35), and 
1.40 (95% CI, 0.83-2.37) among women who were screened (ndeceased=26).   
 
Discussion 
In this population-based study we did not observe any associations between HT and the risk of 
colorectal cancer mortality or all-cause mortality, regardless of its definition.  Among women 
with proximal colon cancer diagnoses, a modest increased risk of both colorectal cancer and all-
cause mortality was observed among long-term users of HT that was attenuated with increasing 
time since last use of HT.  Our confidence in these study results is enhanced by the population 
based nature of our study, and our ability to adjust for important confounders not available in 
prior studies, especially screening history.  
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Our results appear to be in contrast with previous studies of HT use and colon cancer mortality in 
two previous cohorts of cases; both found inverse relationships between HT use prior to 
diagnosis and mortality[13, 14]. Slattery et al. found that, after a mean 7 years of follow-up after 
colon cancer diagnosis, women who had ever used HT had a statistically significant 40% lower 
risk of  colorectal cancer mortality than non-users [14].  Similarly, Mandelson et al., after 6 years 
of follow-up, also showed a reduction in mortality associated with HT use, although this 
reduction appeared to be limited to lesions in the distal colon (hazard ratio=0.33, 95% CI, 0.13-
0.83) [13].  Notably, neither study adjusted for history of endoscopy screening.  These effects of 
screening on colorectal cancer prognosis make this a potentially important confounder in 
epidemiologic studies of colorectal cancer.  In a post-hoc analysis, although our study did not 
find differences in risk when screening was removed from our models, we did observe that HT 
users were more likely to have been screened and been diagnosed with more localized cancers 
that non-HT users.  Women with a history of screening were also more likely to have localized 
disease (45% and 40% of women diagnosed with localized disease for screened and unscreened, 
respectively).  Additionally, the Mandelson et al. study [13] relied on linkages of pharmacy 
records to medical records, and thus it was not possible to adjust for other potential important 
correlates of HT, such as body mass index.  In prior studies examining overall mortality among 
cohorts of healthy women, the relationship with HT use has been modestly inverse, with the 
greatest reductions in risk among current HT users [15, 24-26].  Such a finding is likely 
consistent with the strong reductions in incidence associated with current HT use, which is 
impossible to separate from an association with mortality in this design.    
 
11 
Based upon these limited studies and contradictory results, it is difficult to reach a consensus on 
the relationship between HT use and colorectal cancer mortality.  There is some evidence that the 
association between HT and colorectal cancer incidence varies by stage of disease. In the 
Women’s Health Initiative (WHI) trial, women who used estrogen plus progestin were more 
likely to be diagnosed at an advanced stage of disease (i.e. regional or metastatic) than cases in 
the placebo arm (76.2% vs. 48.5%, p=0.004, ref.[5]).  After adjustment for stage at diagnosis, no 
increased or decreased risk of colorectal cancer mortality was observed among our cohort of 
women.  Thus our results appear to be consistent with this randomized controlled trial.  
 
When interpreting the results of this study, several limitations should be considered. We 
measured HT use 1-2 years prior to diagnosis, and did not evaluate HT use after diagnosis. Thus, 
there could be some misclassification of the exposure if women who were non-users initiated HT 
use after their colorectal cancer diagnosis, or selectively continued HT use.  Such treatment 
patterns would be relatively unlikely since, in general as a promoter, HT is often contraindicated 
after a diagnosis of some cancers because of its growth promoting properties [27].  We were 
unable to interview all eligible cases, and 17% of women were deceased before we could enroll 
them. The loss of subjects due to death is always raises concerns about the possibility of survival 
bias.  However, the results of our case-control study, upon which this study is based, found a 
strong inverse association with HT that was consistent with the findings of other prospective 
studies, as well as the Women’s Health Initiative, where losses to death were not an issue [2-11]. 
Women in the study who reported use of HT, however, were actually slightly more likely than 
non-users to be diagnosed at an earlier stage, so bias towards the null due to advanced stage 
appears unlikely to explain these results.  In addition, our previous study of body mass and 
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colorectal cancer mortality [20], found no differences in associations with mortality among the 
different stages of cancer diagnoses.  Finally, our sample sizes for several subcategories were 
quite small, thus limiting our ability to detect some associations of interest, and limiting our 
ability to assess effect modification; these results may also be due to chance due to the limited 
power and multiple comparisons.  
There is ample biologic plausibility that estrogens may exert an effect on colorectal cancer 
incidence [1], possibly through several mechanisms.  Indeed, the colon contains hormone 
receptors that are likely pivotal in its responsiveness to sex hormones[28].  However, the 
mechanisms by which HT use might impact survival remain poorly studied.   In our study, 
women who developed incident proximal colon cancer even while using HT prior to diagnosis 
may have developed tumors resistant to the benefits of HT.  If these women develop colon 
cancer despite exogenous estrogen use, other genetic or environmental factors predisposing 
women to colorectal cancer may predominate.  The presence of differential etiologic pathways 
predominating in users versus non-users of HT by colon cancer site needs to be explored, in the 
laboratory, clinic, and population. 
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n % n %
Age at diagnosis
  40-54 166 16.7 64 18.0
  55-59 108 10.9 55 15.4
  60-64 167 16.8 60 16.9
  65-70 269 27.1 91 25.6
  70-74 282 28.4 86 24.2
Cancer site
  Colon 815 82.2 299 84.0
  Rectum 177 17.8 57 16.0
Extent of disease/stage
  Local 392 39.5 171 48.0
  Regional 476 48.0 150 42.1
  Distant 79 8.0 20 5.6
  Unknown 45 4.5 15 4.2
Body mass index (kg/m2)
  <22.5 236 23.8 90 25.3
  22.5-25.4 226 22.8 92 25.8
  25.5-28.9 245 24.7 92 25.8
  ≥29.0 266 26.8 81 22.8
Family history of colorectal cancer
  No 767 77.3 279 78.4
  Yes 179 18.0 68 19.1
  Unknown 46 4.6 9 2.5
Smoking status
  Never 517 52.1 160 44.9
  Former 263 26.5 134 37.6
  Current 206 20.8 62 17.4
History of endoscopy screening
  No 661 66.6 213 59.8
  Yes 315 31.8 142 39.9
  Unknown 16 1.6 1 0.3
Table 1.  Baseline characteristics of postmenopausal women with incident colorectal cancer, 
Wisconsin (1988-91 and 1997-2001).
(N=992) (N=356)
Ever used hormone therapyNever used hormone therapy
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Hormone Therapy
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
  Never† 213 1.00 reference 172 1.00 reference 58 1.00 reference 101 1.00 reference 41 1.00 reference
  Ever 61 1.08 0.80-1.46 48 1.03 0.73-1.45 21 0.99 0.56-1.74 20 0.90 0.53-1.53 13 1.26 0.58-2.71
    Former 21 0.87 0.55-1.35 17 0.87 0.52-1.46 7 0.71 0.31-1.61 8 0.98 0.46-2.12 4 0.77 0.23-2.51
    Current 40 1.25 0.87-1.81 31 1.16 0.76-1.77 14 1.34 0.66-2.73 12 0.84 0.43-1.63 9 1.81 0.71-4.58
Duration of Use in Years
  <5 29 1.08 0.72-1.61 21 0.94 0.59-1.50 7 0.82 0.21-1.27 10 0.98 0.49-1.96 8 1.42 0.54-3.74
  ≥5 32 1.08 0.73-1.60 27 1.12 0.72-1.74 14 1.53 0.82-3.10 10 0.82 0.41-1.66 5 1.09 0.38-3.14
  Continuous, per year 1.01 0.99-1.04 1.01 0.98-1.04 1.04 1.00-1.07 0.98 0.92-1.03 1.02 0.95-1.08
     p-value 0.44 0.54 0.04 0.37 0.63
Type of Treatment
  Estrogen only 41 1.18 0.53-1.68 34 1.16 0.78-1.71 13 0.83 0.42-1.64 15 1.28 0.71-2.33 7 1.17 0.46-2.95
  Estrogen/Progestin 13 1.13 0.63-2.04 9 0.94 0.46-1.92 6 2.31 0.89-5.99 2 0.3 0.07-1.33 4 3.32 0.62-17.82
  Other/Unknown 7 0.68 0.31-1.45 5 0.65 0.27-1.62 2 0.71 0.16-3.12 3 0.67 0.21-2.19 2 0.87 0.19-3.95
Table 2. Colorectal cancer mortality in women by use of hormone therapy and cancer site
* Proportional hazards models stratified on phase of study and age at diagnosis, and adjusted for menopausal status, body mass index, extent of disease 
  screening, smoking status, family history of colorectal cancer, and time from date of diagnosis to interview.
† Reference category.
Colorectal cases Colon cases Rectal casesProximal Colon cases Distal Colon cases
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Hormone Therapy
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
Number of 
Deaths HRR*  95%CI
  Never† 329 1.00 reference 127 1.00 reference 183 1.00 reference 79 1.00 reference
  Ever 80 0.88 0.68-1.14 38 0.92 0.62-1.37 34 0.76 0.51-1.12 19 0.77 0.43-1.37
    Former 39 0.89 0.63-1.25 19 0.87 0.48-1.34 18 0.92 0.55-1.53 8 0.55 0.25-1.24
    Current 41 0.87 0.61-1.24 19 0.98 0.63-1.91 16 0.63 0.36-1.09 11 1.09 0.51-2.30
Duration of Use in Years
  <5 40 0.95 0.68-1.34 18 1.03 0.50-1.45 18 0.86 0.52-1.44 13 0.97 0.49-1.95
  ≥5 40 0.82 0.58-1.15 20 1.08 0.59-1.68 16 0.67 0.39-1.14 6 0.55 0.22-1.33
  Continuous, per year 0.99 0.97-1.02 1.03 1.00-1.06 0.97 0.93-1.01 0.98 0.93-1.04
     p-value 0.59 0.08 0.10 0.58
Type of Treatment
  Estrogen 53 0.91 0.67-1.22 24 0.82 0.51-1.32 22 0.85 0.53-1.37 9 0.60 0.28-1.26
  Estrogen/Progestin 11 0.64 0.34-1.20 7 1.41 0.62-3.23 3 0.28 0.09-0.91 5 2.36 0.66-8.42
  Other/Unknown 16 1.03 0.62-1.71 7 0.99 0.44-2.20 9 1 0.50-1.99 5 0.79 0.29-2.14
* Proportional hazards models stratified on phase of study and age at diagnosis, and adjusted for menopausal status, body mass index, extent of disease
  screening, smoking status, family history of colorectal cancer, and time from date of diagnosis to interview.
† Reference category.
Table 3. All-cause mortality in women by use of hormone therapy and cancer site
Colon cases Rectal casesProximal colon cases Distal colon cases
 
 
 
 
  
 
 
 
 
 
 
 
